Treatment with the small-molecule KDM6A/6B inhibitor GSK-J4 increased chemotherapy sensitivity and attenuated the malignant phenotype in CRC cells by increasing H3K27me3 levels [27,29]. The gene discussed is KDM6A; the disease is colorectal carcinoma.